FDA grants Fast Track to VIR-5500 for metastatic prostate cancer

VIR-5500, co-developed with Astellas, received FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer. Fast Track status accelerates review timelines and increases odds of regulatory success, though it is not a guarantee of approval and represents an earlier-stage milestone than Phase 3 data or NDA acceptance.

The FDA gave VIR's cancer drug a faster review track, which is good news but not a guaranteed approval. It means the agency thinks the drug could be important and will review it more quickly.